Evinacumab is a Monoclonal Antibody owned by Regeneron Pharmaceuticals, and is involved in 12 clinical trials, of which 8 were completed, 3 are ongoing, and 1 is planned. Evinacumab is a recombinant human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3). ANGPTL3 is an inhibitor of lipoprotein lipase and endothelial lipase. These lipases are involve in metabolism of lipoproteins. This increases levels of plasma triglycerides, as well as low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol.

The revenue for Evinacumab is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Evinacumab NPV Report.

Evinacumab is originated and owned by Regeneron Pharmaceuticals. Ultragenyx Pharmaceutical is the other company associated in development or marketing of Evinacumab.

Evinacumab Overview

Evinacumab (Evkeeza) is a fully human monoclonal antibody, acts as anti-hypercholesterolemia. It is formulated as injectable solution, and concentrate solution for intravenous route of administration. Evkeeza is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).

Evinacumab (REGN-1500) is under development for the treatment of dyslipidemia in homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia and severe forms of hypertriglyceridemia. It is under development for the prevention of acute pancreatitis prevention. The drug candidate is administered through subcutaneous and intravenous route. It targets angiopoietin-like 3. The therapeutic candidate is a monoclonal antibody developed based on the VelocImmune technology.

Ultragenyx Pharmaceutical Overview

Ultragenyx Pharmaceutical (Ultragenyx) develops novel medicines for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of glycogen storage disease type Ia, or GSDIa; UX701 for Wilson disease; UX053 for glycogen storage disease type III; and GTX-102 for Angelman syndrome in partnership with GeneTx. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

The company reported revenues of (US Dollars) US$351.4 million for the fiscal year ended December 2021 (FY2021), an increase of 29.7% over FY2020. The operating loss of the company was US$381.7 million in FY2021, compared to an operating loss of US$330.1 million in FY2020. The net loss of the company was US$454 million in FY2021, compared to a net loss of US$186.6 million in FY2020. The company reported revenues of US$90.7 million for the third quarter ended September 2022, an increase of 1.5% over the previous quarter.

Quick View – Evinacumab

Report Segments
  • Innovator (NME)
Drug Name
  • Evinacumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.